80171-33-1

Usage

Uses

Used in Pharmaceutical Industry:
NSC49419 is used as an HDAC2 inhibitor for its potential to regulate gene expression and chromatin structure, which may contribute to anti-inflammatory and anti-cancer effects. This makes it a candidate for the development of treatments for rheumatoid arthritis and certain types of cancer.
Further research is necessary to fully elucidate the therapeutic potential and mechanisms of action of NSC49419, but its role as an HDAC2 inhibitor suggests it could be a novel target for drug development in the treatment of inflammatory and neoplastic diseases.

InChI:InChI=1/C10H8N2O3/c13-7-3-1-6(2-4-7)5-8-9(14)12-10(15)11-8/h1-5,13H,(H2,11,12,14,15)/b8-5-

Upstream product

• 6318-40-7 (5Z)-5-(4-hydroxybenzylidene)-2-thioxoimidazolidin-4-one 
• 461-72-3 2,4-imidazolidinedione 
• 123-08-0 4-hydroxy-benzaldehyde 
• 110-89-4 piperidine 

Downstream Products

• 156-39-8 4-hydroxyphenylpiruvic acid 
• 58942-04-4 5-(4-hydroxy-benzyl)-imidazolidine-2,4-dione 
• 154292-21-4 5-(4-(benzyloxy)benzylidene)imidazolidine-2,4-dione 
• 402609-20-5 5-(4-((2-chlorobenzyl)oxy)benzylidene)imidazolidine-2,4-dione 

Relevant academic research and scientific papers

Design, synthesis, biological evaluation and molecular dynamics simulation studies of imidazolidine-2,4-dione derivatives as novel PTP1B inhibitors

Protein tyrosine phosphatase 1B (PTP1B) is a member of the phosphotyrosine phosphatase family and plays an important role in the signal transduction of diabetes. Inhibition of PTP1B activity can increase insulin sensitivity and reduce blood sugar levels.

Butenolide derivative as well as preparation method and application thereof

The invention discloses a butenolide compound as well as a preparation method and an application thereof. The butenolide derivative has the inhibitory activity of protein tyrosine phosphatase 1B (PTP1B), improves insulin resistance of HepG2 cells, generates a remarkable hypoglycemic effect and can be used for preparing a medicine for treating diabetes mellitus.

Furanone compound and preparation method and application thereof

The invention discloses a furanone compound and a preparation method and application thereof. P-hydroxybenzaldehyde is used as a raw material, condensed with hydantoin and then subjected to alkaline hydrolysis and esterification to obtain a p-hydroxyphenylpyruvate intermediate; p-hydroxy benzaldehyde and halogenated isopentene are subjected to alkylation, and then benzyl protection is performed toobtain a benzaldehyde derivative intermediate; a benzaldehyde derivative intermediate and a phenylpyruvate intermediate are subjected to aldol condensation and intramolecular esterification under thecatalysis of a condensing agent to synthesize novel furanone compounds BL5 and BL10. The furanone derivative has H1N1 virus inhibition activity, and can be used for preparing medicines for treating H1N1 virus infection.

Benzylidene azo lysine derivative or its salt bleaching agent and anti-light-aging agent

PROBLEM TO BE SOLVED: To provide a novel whitening agent, an anti-photoaging agent, a tyrosinase inhibitor, a melanogenesis inhibitor, a reactive oxygen species generation inhibitor, a SOD-like activator, and a catalase-like activator.SOLUTION: The invent

Design, synthesis, and biological evaluation of substrate-competitive inhibitors of C-terminal Binding Protein (CtBP)

C-terminal Binding Protein (CtBP) is a transcriptional co-regulator that downregulates the expression of many tumor-suppressor genes. Utilizing a crystal structure of CtBP with its substrate 4-methylthio-2-oxobutyric acid (MTOB) and NAD+ as a guide, we have designed, synthesized, and tested a series of small molecule inhibitors of CtBP. From our first round of compounds, we identified 2-(hydroxyimino)-3-phenylpropanoic acid as a potent CtBP inhibitor (IC50 = 0.24 μM). A structure-activity relationship study of this compound further identified the 4-chloro- (IC50 = 0.18 μM) and 3-chloro- (IC50 = 0.17 μM) analogues as additional potent CtBP inhibitors. Evaluation of the hydroxyimine analogues in a short-term cell growth/viability assay showed that the 4-chloro- and 3-chloro-analogues are 2-fold and 4-fold more potent, respectively, than the MTOB control. A functional cellular assay using a CtBP-specific transcriptional readout revealed that the 4-chloro- and 3-chloro-hydroxyimine analogues were able to block CtBP transcriptional repression activity. This data suggests that substrate-competitive inhibition of CtBP dehydrogenase activity is a potential mechanism to reactivate tumor-suppressor gene expression as a therapeutic strategy for cancer.

Synthesis, biological evaluation and molecular modeling studies of psammaplin A and its analogs as potent histone deacetylases inhibitors and cytotoxic agents

In this study, a concise synthetic method of psammaplin A was achieved from 3-bromo-4-hydroxybenzaldahyde and hydantoin through a four-step synthesis via Knoevenagel condensation, hydrolysis, oximation and amidation in 37% overall yield. A collection of novel psammaplin A analogs focused on the variations of substituents at the benzene ring and modifications at the oxime moiety were synthesized. Among all the synthesized compounds, 5d and 5e showed better HDAC inhibition than psammaplin A and comparable cytotoxicity against four cancer cell lines (PC-3, MCF-7, A549 and HL-60). Molecular docking and dynamics simulation revealed that (i) hydrogen atom of the oxime group interacts with Asp99 of HDAC1 through a water bridged hydrogen bond and (ii) a hydroxyl group is optimal attached on the para-position of benzene, interacting with Glu203 at the entrance to the active site tunnel.

New compounds having skin whitening, antioxidant and PPAR activity, and medical use thereof

PURPOSE: A novel compound with skin whitening, antioxidation, and PPAR activation effects, and a medical use thereof are provided to be used for a pharmaceutical composition or a cosmetic product. CONSTITUTION: A compound is denoted by chemical formula 1. A skin whitening composition contains the compound as an active ingredient. An antioxidative composition for preventing or treating oxidative diseases contains the compound of chemical formula 1 as an active ingredient. The oxidative diseases are selected among skin aging, pigmentation, wrinkling, psoriasis, or eczema. The composition prevents or treats diseases which are regulated by PPAR(peroxisome proliferator-activated receptor) activity. The PPAR includes PPAR alpha or PPAR gamma.

Synthesis, biological evaluation and 3D-QSAR studies of imidazolidine-2,4-dione derivatives as novel protein tyrosine phosphatase 1B inhibitors

Protein tyrosine phosphatase 1B (PTP1B) plays a vital role in the regulation of insulin sensitivity and dephosphorylation of the insulin receptor, so PTP1B inhibitors may be potential agents to treat type 2 diabetes. In this work, a series of novel imidazolidine-2,4-dione derivatives were designed, synthesized and assayed for their PTP1B inhibitory activities. These compounds exhibited potent activities with IC50 values at 0.57-172 μM. A 3D-QSAR study using CoMFA and CoMSIA techniques was carried out to explore structure activity relationship of these molecules. The CoMSIA model was more predictive with q2 Combining double low line 0.777, r2 Combining double low line 0.999, SEE Combining double low line 0.013 and r2pred Combining double low line 0.836, while the CoMFA model gave q2 Combining double low line 0.543, r2 Combining double low line 0.998, SEE Combining double low line 0.029 and r2pred Combining double low line 0.754. The contour maps derived from the best CoMFA and CoMSIA models combined with docking analysis provided good insights into the structural features relevant to the bioactivity, and could be used in the molecular design of novel imidazolidine-2,4-dione derivatives.

NOVEL BENZYLIDENE AZOLIDINE DERIVATIVE OR SALT THEREOF

Provided is a novel compound which has excellent ultraviolet-absorbing function (especially UVA absorbing function) and excellent hydrophilicity. A benzylidene azolidine derivative of the present invention or a salt thereof is characterized by being a ben

SHIKIMATE PATHWAY INHIBITORS AND THE USE THEREOF

The present invention relates to methods of inhibiting shikimate pathway, comprising administering to a subject a pharmaceutically acceptable composition comprising a compound having a formula: or pharmaceutically acceptable salts thereof. The present invention also provides a synergistic antibacterial composition containing compound